CVS Caremark has selected Novo Nordisk’s Wegovy as the preferred GLP-1 medication for its largest commercial template formularies, effective July 1.
In March, Novo Nordisk launched NovoCare Pharmacy to provide direct-to-patient doses of Wegovy for $499 per month. Eligible self-paying patients can also get the $499-per-month price at their local pharmacy.
The new formulary change is a blow to Eli Lilly, which began selling higher doses of Zepbound, a weight loss drug, for $499 at first fill in late February. The 7.5-milligram and 10-milligram single-dose vials are then sold for $599 and $699, respectively, through its direct-to-consumer platform. A CVS spokesperson told CNBC that the PBM secured a lower net price for Wegovy compared to Zepbound on its primary formularies, providing cost savings to clients who choose those plans.
Novo Nordisk also expanded its GLP-1 partnership with Humana’s CenterWell Pharmacy in late April to further increase access to Wegovy through direct-to-patient delivery and telehealth services. Telehealth providers Hims & Hers Health, LifeMD, and Ro will work directly with NovoCare to prescribe Wegovy to self-pay patients, and CenterWell will manage prescription fulfillment and home delivery.
According to a major clinical trial published in the New England Journal of Medicine on April 30, Wegovy reduced liver inflammation in 63% of patients with the serious liver disease MASH, compared to 34.3% in the placebo group, and improved liver fibrosis in 37% of patients versus 22.4% in the placebo group.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
